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Executive Summary
Because the desire to have one’s own biological children can be strong and compelling, the effects of infertility 
for individuals or couples who are unable to conceive can be devastating. Infertility or its treatment can cause 
psychological stress, anxiety, and depression. Treatment of infertility can be medically invasive and may cause 
discomfort or, in some cases, be associated with health problems for women, men, and the resulting children. 
Given the goal of public health is to reduce disease, premature death, injury, and disability through prevention 
and health promotion, preventing infertility and the adverse consequences associated with its treatment are 
important concerns. A clear need exists to identify public health priorities regarding infertility and its effect on 
health.
Infertility may be caused by a myriad of factors including genetic abnormalities, aging, acute and chronic 
diseases, treatments for certain conditions, behavioral factors, and exposure to environmental, occupational, 
and infectious agents. However, many questions about infertility remain unanswered. In addition, significant 
disparities exist by race, ethnicity, sex, and socioeconomic status in the prevalence, diagnosis, referral, and 
treatment of infertility. Furthermore, treatments for infertility can carry health risks for women, men, and their 
children. This publication addresses these issues, focusing on the public health aspects of infertility detection, 
prevention, and management.
Description of the National Public Health Action Plan
In consultation with many governmental and nongovernmental partners, the Centers for Disease Control 
and Prevention (CDC) developed the National Public Health Action Plan for the Detection, Prevention, and 
Management of Infertility (hereafter called the National Action Plan or the Plan ). This plan highlights the need 
to better understand and address issues at a population level that contribute to and are caused by infertility in 
women and men and that may affect the health of the pregnancy. 
Specifically, this plan focuses on:
1. Promoting healthy behaviors that can help maintain and preserve fertility.
2. Promoting prevention, early detection, and treatment of medical conditions that can threaten fertility.
3. Reducing exposures to environmental, occupational, infectious, and iatrogenic agents that can threaten fertility.
Because of its public health focus, these strategies also call for promoting healthy pregnancy outcomes 
associated with treating and managing infertility and improving the safety and efficacy of infertility treatments. 
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Introduction 
In general, infertility refers to the inability of couples to conceive a clinical pregnancy after 1 year or more of 
trying.1 However, definitions for infertility vary widely depending on the type of information available and the 
purpose for which the information is collected.2 For example, some clinical definitions of infertility include 
women aged 35 years or older after 6 months of trying to conceive. Further delaying the initiation of infertility 
interventions could limit their effectiveness. In contrast, demographic definitions of infertility often encompass 
the inability to have a live birth among sexually active women who are not using contraception. These 
definitions better meet the needs and constraints of demographic research because of the difficulty in collecting 
complete information about conception, particularly in studies conducted in developing nations.3 Regardless, 
the true burden of infertility may be underestimated because neither definition necessarily reflects people who 
may have stopped trying or who have experienced infertility in the past.
Infertility can take several different forms, including resolved infertility (pregnancies that occur after 1 year of 
trying without medical intervention), primary infertility (never pregnant), or secondary infertility (failure to 
conceive after having previously delivered an infant without the use of infertility treatment). Other conditions 
related to infertility are also important to consider when assessing the effect of infertility on public health. 
Fecundability refers to the probability of becoming pregnant in a single menstrual cycle, conditional on not 
being pregnant in the previous cycle.3 Impaired fecundity has been defined as physical difficulty in getting 
pregnant or carrying a pregnancy to term birth.4 Because this publication draws on many different sources of 
information regarding infertility, we use these terms broadly and cite references for more specific definitions as 
needed. 
Public Health Priority 
Although the ability to have children is often assumed, a significant proportion of individuals and couples 
experience infertility and may be affected by its resulting social, economic, psychological, and physical effects. 
The ability to have children represents more than a quality-of-life issue. The World Health Organization 
(WHO) and other professional organizations, such as the American Society for Reproductive Medicine, have 
defined infertility as a disease.1,5 Early environmental, chemical, or occupational exposures (e.g., in utero, in 
childhood) could permanently change fecundity or biologic capacity by affecting gynecologic, urologic, or 
pregnancy health. These exposures could also affect fertility outcomes (e.g., multiple births, prematurity) and 
increase the likelihood of later adult-onset diseases, such as ovarian, testicular, or prostate cancers,6-9 metabolic 
syndrome, and polycystic ovary syndrome. In this way, infertility may serve as a marker of past, present, and 
future health and provide a window of opportunity to improve care for affected reproductive-aged women and 
men. Thus, infertility could have public health implications beyond simply the ability to have children.
Infertility affects a substantial percentage of reproductive-aged women and men in the United States. One 
approach to estimating infertility considers the entire population of women and men of reproductive age, 
regardless of current fertility intentions. Nationally representative data using this approach have come from 
CDC’s National Survey of Family Growth (NSFG) dating back to the early 1980s; the most recent data from 
the 2006–2010 survey show that, among all married US women aged 15–44 years, 6.0% or an estimated 
1.5 million women (and thus their husbands) were infertile and 12% (or 3.1 million women) had impaired 
fecundity.4 A second approach to estimating infertility considers only the population of reproductive-aged 
women (and their partners) at risk for infertility, such as those who are actively trying to become pregnant. 
Studies using this approach have generally yielded higher estimates of infertility. A review of previous US 
studies, most of which were small and not nationally representative, for example, suggested as many as 
12%–18% of couples do not achieve pregnancy within 12 months or cycles of trying.10 Estimates from earlier, 
nationally representative data from the 2002 NSFG among a similar population of women (and their partners) 
who were trying to become pregnant indicate that a comparable proportion (16%) were infertile.10,11    
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For males, some form of infertility was reported by 9% of men, again according to CDC’s NSFG conducted 
from 2006–2010.4 As with women, the percentage of men reporting infertility was higher when assessing those 
couples who were trying to become pregnant. Estimates from the earlier NSFG sample of males from 2002, 
for example, suggest that 12% of couples may be affected by infertility.12
Environmental and occupational hazards account for an unknown proportion of male infertility but are 
suspected causes of declining human sperm quality in industrialized countries.13-15 The proportion of infertility 
cases attributable to male-specific factors may be substantial. One earlier evaluation conducted in developed 
countries in the 1980s by WHO found that 8% of infertility cases were attributable to male factors and 
35% to both male and female factors, whereas 37% were attributable to female factors alone and 5% to an 
unknown cause (the remaining 15% of women became pregnant).16 Another evaluation estimated that male 
factors account for approximately 20% of couple infertility, with another 30%–40% of cases attributable to 
reproductive abnormalities that were present in both partners.17
The natural age limits of fertility in both women and men have become more apparent with the recent trend 
toward delaying childbearing in the United States.18-21 The percentage of first births among women aged 30 
years or older increased from 5% in 1975 to 26% in 2010.22,23 Infertility also remains closely associated with 
age, especially for nulliparous (i.e., childless) women. Recent data from the NSFG, for instance, indicate 
that among nulliparous women, the percentage experiencing infertility increases markedly with age, from 
7%–9% among those aged 15–34 years to 25% among those aged 35–39 years and 30% among those aged 
40–44 years.4 As women age, the risk of infertility rises because of diminished egg quality and ovulatory 
function and because of an increased risk of disorders such as endometriosis, leiomyomata, and tubal disease.24
Advanced paternal age also might contribute to infertility through reductions in the quality and quantity of 
sperm produced.20,21,25 The combination of the high proportion of pregnancies in the United States that are 
unintended (about 50%)26 and the rise in intended pregnancy at later ages, when infertility is increasingly 
common, indicates a basic need for improved education on family planning, infertility, and other reproductive 
health issues for people who may want children in the future.
In the United States, data from the 2006–2010 NSFG 27 also show:
• 12% of women of reproductive age (7.3 million women), or their husbands or partners, had ever used
infertility services in their lifetime
• The percentage of women seeking such services increased with age and was approximately 20% among
women aged 35–44 years
• About 9% of sexually experienced US men aged 25–44 years reported they or their wives or partners had
ever used infertility services to help have a child
Services and treatments for infertility range from counseling and advice to medications and surgery. The most 
common medical services received by reproductive-aged women with current infertility problems were those 
at the lower end of cost and complexity including advice (29%), testing of her or her male partner (27%), and 
ovulation medications (20%). Less commonly received services included intrauterine insemination (IUI) (7%), 
surgery or treatment for blocked tubes (3%), and assisted reproductive technology (ART) (3%).
Treatments for infertility can carry significant health risks to the mother and child. For example, a very 
rare but serious risk of using drugs for ovulation induction is ovarian hyperstimulation syndrome (OHSS), 
which is characterized by enlargement of the ovary and an accumulation of fluid in the abdomen.28 OHSS is 
usually self-limiting, resolving spontaneously within several days, though the most severe cases may require 
hospitalization and intensive care. In addition, some (but not all) research suggests that infertility treatments 
may be associated with an increased risk of gynecologic or breast cancer.29,30 Infertility treatments have 
increased the rate of twin and higher-order multiple births, which put both mother and infants at higher risk 
of adverse health outcomes.31-33  Even singleton births resulting from ART are associated with increased risk of 
low birth weight (<2,500 grams).34 Infants who are born to mothers who receive ART35,36 or non-ART (e.g., 
clomiphene citrate)37 treatments may be at higher risk of birth defects.
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Overall, the long-term health risks for women and men receiving treatment for infertility and for children 
born as a result of ART or other treatments are not known.38
Development of the National Public Health Action Plan
In 2007, a CDC-wide ad hoc work group was formed to examine the full scope of infertility activities across 
the agency. This work group conducted an assessment to identify gaps and opportunities in public health 
surveillance, research, communications, programs, and policy development. This assessment led to  
publication of a White Paper outlining the need for a national plan with a public health focus on infertility 
prevention, detection, and management.39 In September 2008, CDC also hosted a symposium “Infertility as 
a Public Health Issue” attended by about 60 stakeholders from Federal agencies, professional and consumer 
organizations, academia, and the health care community. 
In response to interest from Congress40 and stakeholders, CDC developed this National Action Plan to 
promote collaborative activities within and outside the Federal government.  A draft of the document was 
posted on www.regulations.gov for public comment on May 16, 2012. The comment period closed on July 16, 
2012. A total of 58 comments were received and have been incorporated into the strategy as appropriate. Also, 
representatives of several Federal agencies provided comments on the Plan and noted opportunities for future 
collaboration.
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Chapter 1: Detection of Infertility
Public Health Importance 
The clinical detection of infertility is important because it can lead to further evaluation and treatment where 
needed. Similarly, public health surveillance of infertility will be most effective when a standard case definition 
is established for population-based data collection. No definitive test or case definition currently exists for 
infertility.2,3 A range of definitions has been used, and these definitions are often based on a combination of 
the length of time that the couple has been trying to conceive (or to produce a live birth) and the age of the 
woman. A clear, standard definition for infertility is needed to ensure timely care for those who need services 
and to prevent overtreatment for those who may be able to conceive without medical interventions. 
To fully understand the negative effects of infertility in the United States and measure progress toward 
reducing the problem, increased attention is needed to the ongoing collection, analysis, interpretation, and 
use of population-level data related to infertility. Specifically, researchers need to measure four types of data 
on a recurring basis: (1) disease incidence and prevalence; (2) prevalence of risk factors for various types 
of infertility; (3) access to and use, safety, efficacy, and quality of infertility services; and (4) economic and 
financial aspects of service delivery.
1. Disease incidence and prevalence.
Measurement of disease incidence and prevalence at the population level requires surveillance of infertility,
including the type(s) of infertility, and the spectrum of disorders and conditions that directly contribute to the
diagnosis—each of which has different implications for detection, prevention, and management.
Other key indicators to monitor include semen quality, time-to-pregnancy, recurrent pregnancy loss, male and
female sterilization (as well as sterilization reversal), and resolved infertility. Researchers also need to estimate
and track the size of subpopulations that may need or potentially benefit from fertility preservation. For
example, people with cancer, autoimmune disorders, or bleeding or clotting disorders may benefit from fertility
preservation methods such as the use of drugs to protect the ovaries during chemotherapy or cryopreservation of
ovarian or testis tissue, eggs or sperm, or embryos obtained through in vitro fertilization.
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2. Prevalence of risk factors for various types of infertility. 
Surveillance of possible risk factors for infertility should include data on sociodemographic characteristics (e.g., 
age, race/ethnicity, education, place of residence, socioeconomic status), health behaviors (e.g., use of alcohol, 
tobacco, illicit drugs, anabolic steroids), body weight and related factors, adherence to screening and treatment 
recommendations related to risk factors, physical and mental health conditions (e.g., genetic disorders, sexually 
transmitted infection (STI), obesity, depression, cancer), environmental exposures (e.g., household chemicals), 
occupational exposures (e.g., industry type, specific occupations, identified chemical or physical exposures in the 
workplace), and prenatal and intergenerational exposures (e.g., diethylstilbestrol).
3. Access to and use, safety, efficacy, and quality of infertility services. 
Collection of population-based data on access to and use and quality of infertility services requires the 
identification of key indicators related to screening, diagnosis, laboratory services, state-specific infertility 
treatment mandates, and psychosocial determinants (e.g., fertility goals). These indicators may influence 
service-seeking behavior, counseling, and treatment decisions. 
4. Economic and financial aspects of service delivery. 
Finally, to estimate and track the economic and financial aspects of service delivery, researchers need to collect 
data in several areas. Examples include the use and cost of infertility services, the cost of infertility treatment, 
the direct and indirect costs of untreated and treated infertility (regardless of the reproductive outcome), 
and the cost-effectiveness of alternative treatment strategies. Data are also needed on the economic effect of 
reducing barriers to diagnosis and treatment and the long-term health care costs of adverse maternal and child 
outcomes related to infertility treatment.
The Challenge
Clinical Detection and Surveillance
To facilitate comparisons of infertility estimates across clinic and population-based studies, clinical detection 
and public health surveillance of infertility should be based on standard diagnostic criteria and case definitions 
for both male and female infertility. Appropriate clinical and behavioral indicators are needed to improve the 
detection of infertility in the US population. To effectively prevent and manage infertility, the clinical diagnosis 
must be based on scientific evidence. Public health surveillance of infertility depends on the systematic, 
recurring collection and management of accurate data. Ideally, surveillance systems that capture infertility 
data will use standard case definitions that can be applied across multiple data systems and over time. For 
surveillance to be maximally effective and useful, the data collected must identify types of infertility, including 
specific infertility diagnoses, and associated risk factors and outcomes. 
Several public health surveillance systems include ongoing, population-based surveys that currently collect 
data on a variety of reproductive behaviors, infertility treatments and services sought, and outcomes. Examples 
include CDC-directed systems such as the National Vital Statistics System (NVSS), National ART Surveillance 
System (NASS), Pregnancy Risk Assessment Monitoring System (PRAMS), National Health and Nutrition 
Examination Survey (NHANES), and the aforementioned NSFG. The current systems, described further at 
the end of the plan, all have several limitations, such as the lack of uniform case definitions and standardized 
information across systems. For example, methods for quantifying infertility and impaired fecundity can 
differ by data source. Information is lacking on many key indicators, such as the prevalence of specific types of 
infertility for both women and men, the success rates and use of infertility treatments (other than ART) among 
women and men, and adverse maternal and child health outcomes associated with infertility treatment. 
In addition, current surveillance systems do not include measures of all relevant indicators. As a result, these 
systems do not provide a comprehensive assessment of the magnitude of the incidence, prevalence, risk factors, 
and outcomes associated with infertility. These systems could improve the quality of data related to infertility 
by collecting information on the length of time between the start of attempts to conceive and pregnancy or the 
current duration of time spent having unprotected vaginal intercourse.41,42 This information could be reported 
by participants in population-based surveys. Registries of individual cases could also provide information to 
better assess infertility in the population and the safety and effectiveness of treatment. These registries could 
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collect information, for example, on egg donors, patients treated with specific classes of fertility drugs, cancer 
patients who use fertility preservation methods, or military veterans with service-related infertility. Initiatives 
to achieve prospective follow-up of couples planning or at risk for pregnancy are important for establishing 
incidence and attributing clinical factors among couples undergoing infertility evaluations.  
Scientific and Programmatic Opportunities 
The following are specific actions that public sector agencies, professional and consumer organizations, and 
other partners and stakeholders could take to help improve the detection of infertility in the United States.
1. Develop and validate standard case definitions for population-based and clinical surveillance
of infertility.
Development of standard case definitions for infertility and related factors would provide uniform measures for
use in public health and clinical practice. These standard definitions could improve the synthesis of information
and ultimately lead to improved evidence-based guidelines and recommendations for detecting, preventing, and
managing infertility.
2. Improve the surveillance of infertility and related factors.
Population-based surveys could be developed or existing systems could be expanded to support the measuring
and monitoring of the prevalence and incidence of infertility, associated risk factors, and health outcomes in
women, men, and offspring. For example, the NSFG could better evaluate infertility by increasing participant
sample sizes related to the use of infertility treatment, adding new survey questions about experiences with
infertility diagnosis or treatment, and extending its surveys to include older women and men who are more likely
to have experienced infertility.
Questions that directly query women and men about infertility could also be added to other large population-
based surveys (see List of Public Health Surveillance Systems and Surveys Referenced) that currently collect data
relevant to understanding health conditions and factors that may affect fertility. Similarly, to improve the value
of public health surveillance of ART cycles and outcomes and better understand infertility, additional data from
the male partner such as infertility diagnosis and semen quality could be added to the National ART Surveillance
System. Further, multiple records in this system could be linked to allow evaluation of the effectiveness and safety
of ART by patient instead of by treatment cycle. This enhancement would strengthen the ability to evaluate the
short- and long-term effects of ART use on maternal and infant outcomes on a per-patient basis. Finally, the
development of new surveillance systems to monitor the use and health outcomes of non-ART treatments for
infertility should be explored. Birth certificates include information on ART and non-ART treatment that could
also monitor the relationship to adverse pregnancy and birth outcomes. A possible approach for this could be
identifying and including structured data elements to collect such information in electronic health records.
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Chapter 2: Prevention of Infertility
Public Health Importance 
Many questions remain about the prevention of infertility. Although unknown, the proportion of infertility 
that may be preventable is suspected to be substantial.39  Established and possible causes of infertility include 
genetic abnormalities, aging, certain acute and chronic diseases, behavioral risk factors (e.g., body weight, 
smoking),43 and exposure to certain environmental, occupational, and infectious agents. 
One example of a recognized, preventable risk factor for infertility in women and men is untreated sexually 
transmitted infection (STI). In particular, infection with Chlamydia trachomatis increases the risk of pelvic 
inflammatory disease (PID) in women.44-46 If left untreated, PID can cause structural or functional fallopian 
tube damage known as tubal factor infertility. Tubal factor infertility, which may be caused by Chlamydia 
trachomatis or by other infections, such as Neisseria gonorrhoeae, is estimated to affect as many as 18% 
of women using ART to treat infertility.39 Among men, C. trachomatis infection has been linked with 
nongonoccocal urethritis, epididymitis, and lower sperm counts.47 In addition, substantial racial disparities 
have been identified in the rates of chlamydial infection. For example, the prevalence among non-Hispanic 
blacks is about five times higher than among non-Hispanic whites.48 Racial disparities also exist in the rates of 
chronic conditions that affect fertility, such as fibroids.49 Public health monitoring of the prevalence of such 
conditions and associated risk factors can lead to improved identification, guidance, and implementation of 
effective prevention and management strategies.
The Challenge
Understanding the Causes of Infertility
To be able to develop and implement effective public health interventions, researchers need standard case 
definitions for male and female infertility and its causes. Although much is understood about the causes of 
infertility, more research from cohorts that are carefully followed up prospectively would help identify the 
causes and percentage of infertility cases that can be attributed to specific risk factors and medical conditions. 
However, research on infertility is inherently complicated because infertility is generally diagnosed only when 
a man, woman, or couple attempts to become pregnant. People who are not actively trying to conceive will 
typically not have the opportunity to be evaluated or receive a diagnosis of infertility. Current surveillance 
systems are not designed to identify the spectrum of women and men who may have unrecognized infertility.50 
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New methods for measuring infertility and for identifying and improving conditions that are precursors to 
infertility are needed. Improving our understanding about the causes of infertility will enhance preventive and 
therapeutic options for both women and men and reduce our reliance on the use of more invasive methods to 
treat infertility at later stages.
Research is needed to better understand many known and potential causes of infertility, including but not 
limited to the following:
• Reproductive aging—that is, establishing biomarkers, determining the predictors and correlates of early 
depletion of the ovarian reserve, and the effects of age on semen quality and reproductive function.
• Important developmental periods—that is, identifying factors that affect fertility during certain 
developmental periods (e.g., preconception, in utero, puberty, transgeneration) to identify the best time for 
intervention. 
• Infectious diseases—that is, the proportion of cases of tubal factor infertility attributable to infectious diseases 
and the role of specific infections, such as chlamydia, gonorrhea, mycoplasmas, trichomoniasis, bacterial 
vaginosis, tuberculosis of the reproductive tract, microbial organisms associated with reproductive tract 
infections, epididymoorchitis, prostatitis, and mumps.
• Chronic conditions and diseases—including endocrine and metabolic diseases such as primary ovarian 
insufficiency, polycystic ovary syndrome, hypothalamic amenorrhea, menstrual cycle defects, endometriosis, 
uterine leiomyomata, thyroid disorders, metabolic syndrome, diabetes, autoimmune disorders, meiotic 
aneuploidy, cystic fibrosis, varicocele, testicular disorders, multiple sclerosis, general urologic health, and 
immune-mediated disorders.
• Behavioral factors—such as diet, exercise, sleep, psychological and physiological stress, caffeine consumption, 
tobacco and alcohol use, weight gain or loss, nutritional disorders, illicit or prescription drug use, and illicit 
use of anabolic steroids and growth hormones.
• Iatrogenic causes—such as chemotherapy or associated medications for testicular or ovarian cancer and 
antiretroviral therapy for HIV/AIDS.
• Occupational and environmental hazards—such as radiation, repetitive motion or posture, injury (e.g., 
reproductive or urinary tract trauma such as that experienced during military duty), or natural or synthetic 
chemicals and compounds with hormonal activities (e.g., endocrine disruptors).
• Genetic influences—such as male karyotype abnormalities, Y chromosome microdeletions, or androgen 
receptor gene abnormalities. 
Public Health Interventions for Prevention
Public health interventions to prevent infertility must be based on evidence from research. This translation of 
science into public health practice requires the development of systems and policies to incorporate research 
results into prevention programs. The prevention of infertility should be integrated into a broader agenda 
for reproductive health promotion for both women and men. Programs, interventions, strategies, and other 
methods for preventing infertility must be developed and evaluated. Examples of these activities include but 
are not limited to the following:
• Comprehensive approaches to STI screening, treatment, prevention, and education to reduce infertility 
and to address economic and racial disparities in access to STI prevention, testing, and treatment, use of 
infertility services, and outcomes of treatment.51,52
• Interventions to reconcile and clarify simultaneous public health messages for preventing infertility and for 
preventing unintended pregnancy among youth.
• Chronic disease prevention and health promotion programs to reduce the incidence and severity of 
conditions such as diabetes, polycystic ovary syndrome, and infertility related to polycystic ovary syndrome. 
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• Methods to measure reproductive potential (including markers of ovarian reserve and semen analyses) and 
preserve fertility before, during, or after medical therapies that could lead to iatrogenic infertility. 
• Measures to protect the reproductive health and fertility potential of workers who may be exposed to 
environmental and occupational hazards by translating research findings, technologies, and information into 
evidence-based practice.
• Methods to accurately assess environmental and occupational exposures, such as laboratory biomonitoring, 
control technologies, screening tools, and interventions.
• Programs aimed at behavioral factors that may affect infertility, such as programs to prevent use of illicit 
drugs, tobacco, and anabolic steroids; improve nutrition; and promote adequate levels of physical activity.
• Research to determine the cost effectiveness and cost benefit of programs aimed at preventing infertility.
Scientific and Programmatic Opportunities 
The following are specific actions that public sector agencies, professional and consumer organizations, and 
other partners and stakeholders could take to help prevent infertility in the United States.
1. Expand knowledge about infertility prevention through collaborative efforts to identify, prioritize, and 
address research gaps.
Conducting more research on ways to prevent infertility requires collaboration from a range of disciplines, 
including basic science, epidemiology, genomics, and the clinical, behavioral, and social sciences. Governmental 
and nongovernmental organizations must work together to address the gaps in our understanding of the causes 
of both female and male infertility and to increase opportunities for prevention. These efforts should focus on 
several factors, including the effects of age, behavioral risk factors, chronic conditions and diseases and their 
treatment, genetic disorders, and exposure to environmental, occupational, and infectious agents. 
2. Expand laboratory capacity and services to help address knowledge gaps about environmental, 
occupational, and infectious causes of infertility.
Improvements in laboratory-based infertility research would improve our understanding of how environmental, 
occupational, and infectious exposures might adversely affect fertility. For example, public health laboratories 
must be able to conduct biomonitoring of chemicals or their metabolites in human specimens (e.g., blood,  
urine, hair).
3. Increase awareness of the prevalence and known causes of infertility.
Scientific knowledge should be rapidly shared and translated into public health programs and evidence-based 
practices. Educational programs should be developed and conducted to expand awareness among youth and 
adults about the prevalence and known causes of infertility. These programs should be integrated with other 
activities designed to promote reproductive health, and they should take into account the culture and age of 
their audience.
4. Develop and promote behavioral and clinical approaches to preventing infertility based on the best 
scientific evidence available.
Efforts should focus on the design, evaluation, and implementation of programs, interventions, strategies, clinical 
services, and other methods that can effectively address the known causes of infertility (e.g., behaviors that 
increase the risk of infertility). 
5. Support and improve access to quality services, including screening, diagnosis, and treatment services for 
known causes of infertility. 
Further integration of infertility services into primary care settings would help expand access to screening, 
testing, and counseling. In particular, economic and racial disparities in access to and use of infertility services 
and treatment outcomes could be reduced by expanding services at public health and other clinics that target 
underserved populations. To improve the quality of these services, public health providers may need more 
training.
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Chapter 3: Management of Infertility
Public Health Importance 
According to the 2006–2010 NSFG, 12% of women in the United States aged 15–44 years, or their husbands 
or partners, have ever used one or more infertility services.27 This percentage likely underestimates the true 
burden of infertility because it excludes women and men who have not yet sought services. Although most 
infertility services do not involve ART,32 the prevalence of ART use has been increasing. The number of ART 
cycles (which are primarily in vitro fertilization [IVF] cycles) performed in the United States increased from 
99,629 in 2000 to 163,039 in 2011, and ART procedures were used for more than 1% of total births in the 
United States in 2011.18
Fertility treatments can pose health risks for women, men, and their children. For example, the use of drugs to 
induce ovulation can lead to ovarian hyperstimulation syndrome (OHSS), which is characterized by ovarian 
enlargement and which, in serious cases, can cause morbidity and be life-threatening. Infertility treatments, 
including both ART and non-ART procedures in which medications are used to stimulate ovulation, are 
associated with an increased risk of multiple-order births, which carry health risks for women and infants and 
increased costs.33
Infertility treatment can also be expensive, and disparities exist in access to and use of these services. The 
average cost of a single cycle of IVF in the United States has been estimated at more than $12,000.39 Fifteen 
states had laws requiring insurers to cover or offer coverage for some level of infertility treatment in 2006.53 
Insurance coverage could increase the use of elective single embryo transfer in ART procedures, thereby 
improving birth outcomes from these procedures.53 Economic, regional, and racial/ethnic disparities in access 
to and use of infertility services are clearly present.51-54 Even in states with more equitable access to care because 
of insurance mandates, racial/ethnic differences have been found in the rate of adverse health outcomes after 
infertility treatments.51 
More research is needed to improve the management of infertility. This research could:
• Identify new approaches for safe and effective diagnosis and treatment of infertility in women and men that
could reduce the need for ART or other medical approaches to achieve pregnancy.
• Identify and reduce exposure to treatment regimens that pose increased risk of adverse outcomes.
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• Address the ethical and social issues related to certain clinical procedures, as well as the financial costs of 
medically assisted reproduction.
• Eliminate disparities in access to safe and effective treatment for infertility.
The Challenge
New treatments for infertility that are safer and more effective than current treatments need to be developed, 
and more research is needed to improve the safety and efficacy of currently available treatments. Examples 
of current infertility treatments that could be further improved include the following: regimens to induce 
ovulation, adjuvant therapy to enhance the success rates of IVF, regimens to prevent or treat OHSS, methods 
to preserve the integrity of oocytes and embryos, treatments to prevent recurrent pregnancy loss, treatments 
to modify male factors, and, continual efforts to promote overall health across the lifespan. Other areas that 
could be addressed include finding ways to lower the cost of ART treatment, developing treatments that are 
noninvasive or minimally invasive and encouraging their use, and improving infertility management education 
for health care providers.  
Given the increased risks to the health of mothers and infants that are associated with multiple births, 
treatments that do not increase the chances of this outcome are needed. The safety and efficacy of the use 
of donors for infertility management (e.g., oocyte donation, oocyte cryopreservation, sperm donation, 
reproductive tissue donation, gestational surrogacy) should be evaluated for donors, recipients, and children 
conceived.55 In addition, the long-term effects of infertility treatments on adults—as well as on children 
conceived as a result of the treatment—need to be more fully assessed.
More research is needed to improve communications with diverse populations of women and men 
experiencing infertility. Psychological and behavioral research could help improve our understanding of issues 
related to the effect of infertility on their emotional well-being and quality of life and the use of services for 
dealing with infertility, medical and other service-seeking behaviors by individuals and couples experiencing 
infertility, decision-making around the issue of infertility and approaches for single adults and couples trying to 
have children, and the effect of multiple gestation and adverse pregnancy outcomes on parents and children.
Efforts are needed to identify the best methods for providing equitable access to infertility services among 
those in need while minimizing adverse and costly health outcomes, such as those associated with multiple 
births. 
Studies should examine the cost-effectiveness of different treatment methods for women and men (e.g., 
pharmaceutical management versus microsurgical treatment of male or female factors, single embryo transfer 
versus higher-order embryo transfer), including the costs of patient outcomes (e.g., multiple births). These 
investigations could use administrative (e.g., insurance) data and data from other sources. For example, 
if researchers can ensure adequate protection of the security and confidentiality of the data, studies could 
use insurance and hospitalization datasets to monitor the costs related to treating infertility, including 
hospitalization costs, out-of-pocket expenses, and days of work lost. 
Infertility prevention and management practices could potentially be improved by engaging public and private 
payers for those services, conducting cost-effectiveness analyses, developing guidelines and recommendations 
for providers of infertility services, and improving educational information about infertility for the public. 
Guidelines should be based on scientific evidence of the safety and effectiveness of infertility services and 
treatments, and they should take into account multiple considerations. For example, some infertility services, 
such as gestational surrogacy and egg or sperm donation, raise complex ethical, legal, and social questions—
including questions about coercion, payment for surrogates or donors, and ability to follow up with donors to 
assess possible long-term effects on their mental and physical health. Guidelines might also include counseling 
on alternatives for achieving parenthood (e.g., adoption) or choosing to live without children. The appropriate 
use of infertility treatment advances that allow extension of the age at which conception, carrying a pregnancy 
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to term, and delivery may now be achieved must be balanced against another—public health and societal 
interests in preventing adverse health outcomes and excessive health care costs. 
Scientific and Programmatic Opportunities 
The following are specific actions that public sector agencies, professional and consumer organizations, and 
other partners and stakeholders could take to help manage infertility in the United States.
1. Monitor and evaluate the short- and long-term safety of infertility interventions.
Research and enhanced surveillance should focus on the safety, efficacy, and use of different infertility services 
and treatments for managing male and female infertility in different populations. These efforts would improve 
our understanding of the possible short-term effects of infertility treatment. They would also improve our 
understanding of the possible long-term effects of infertility treatment on women and men (regardless of the 
success of the treatment) and on any children conceived as a result of these treatments. 
2. Eliminate disparities in access to high-quality infertility services, including diagnosis, referral,  
and treatment. 
Efforts should focus on reducing disparities in access to, use of, and outcomes related to infertility services. 
Integration of infertility services into primary care settings that target underserved populations could help reduce 
the economic and racial disparities in access to infertility treatment. 
3. Promote further development, adoption, evaluation, and implementation of evidence-based guidelines and 
recommendations that address the prevention, diagnosis, and management of infertility.
Evidence-based guidelines and recommendations for providing infertility services to women and men from 
professional medical associations (such as the American Society for Reproductive Medicine and the American 
Urological Association) should be evaluated on their use and effectiveness, and new guidelines should be 
developed as needed. Guidelines and recommendations should be based on scientific evidence. They should also 
be comprehensive enough to address the numerous—and often complex—issues that surround the management 
of infertility. These issues include complications associated with infertility treatment (e.g., higher-order multiple 
births, OHSS), and bioethical and cost considerations. 
4. Develop educational programs to increase awareness of the safety and effectiveness of treatments for 
infertility and other options for managing infertility. 
Efforts should be made to ensure that health professionals have adequate resources and training to educate 
patients and the public about the benefits and risks of the infertility services available as well as other options for 
dealing with infertility (e.g., adoption). 
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Conclusion
This National Action Plan identifies many opportunities for reducing infertility and its causes in the United 
States. It highlights scientific and programmatic opportunities to strengthen the public health approach 
to detecting, preventing, and managing various types of infertility. Governmental and nongovernmental 
organizations must work together to address the gaps in our understanding of the causes of both female and 
male infertility and to increase opportunities for prevention. Important partners in these efforts should include 
Federal, state, and local agencies; the scientific community; health care professionals; insurance providers; 
employers; industry; nonprofit organizations; and organizations representing people coping with infertility. 
This discussion is critical to the call for action by the White Paper: “… a coordinated and multidisciplinary 
approach to address infertility, from primary prevention to treatment and support.” 39
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List of Public Health Surveillance Systems 
and Surveys Referenced 
National ART Surveillance System 
www.cdc.gov/art/NASS.htm 
In collaboration with the Society for Assisted Reproductive Technology, CDC supports the National ART 
Surveillance System (NASS), a Web-based system for reporting data on assisted reproductive technology 
(ART). This surveillance system captures more than 95% of the estimated ART procedures performed 
annually in the United States. The system collects data on each client’s medical history (such as infertility 
diagnoses), clinical data on the ART procedure, and data on resulting pregnancies and births. Data from NASS 
are used to prepare CDC’s Annual Report on ART Clinic Success Rates.
National Health and Nutrition Examination Survey
www.cdc.gov/nchs/nhanes.htm 
CDC began the National Health and Nutrition Examination Survey (NHANES) program as a series of 
surveys focusing on different population groups or health topics in the early 1960s. The surveys became a 
continuous program in 1999. NHANES uses household and private interview methods to collect annual 
health and nutrition information on a nationally representative sample of noninstitutionalized civilians. 
Health interview topics include the following: current health status, medical conditions, reproductive 
health (pregnancy history, lactation, use of contraception, and men’s and women’s health conditions), health 
insurance coverage, use of health care services, lifestyle behaviors (including sexual, illicit drug, alcohol, and 
tobacco use behaviors), occupational history, and environmental exposure to chemicals. 
National Survey of Family Growth
www.cdc.gov/nchs/NSFG.htm
CDC conducts the National Survery of Family Growth (NSFG) to collect national estimates of the prevalence 
of infertility and impaired fecundity and the use of infertility services in the United States among males 
and females. The survey gathers information on family life, marriage and divorce, pregnancy, infertility, use 
of contraception, and men’s and women’s health. Survey results are used to plan health services and health 
education programs and to conduct statistical studies of families, fertility, and health.  Recently added 
questions to the survey help researchers investigate the associations between cancer history and various factors, 
including the use of infertility services, as well as use of chlamydia screening to assess adherence to current 
CDC screening recommendations. 
National Vital Statistics System
www.cdc.gov/nchs/births.htm
CDC cooperates with the states to maintain the National Vital Statistics System (NVSS), a Federal 
compilation of births and other vital statistics data. Birth certificates contain maternal and paternal 
information (e.g., education, race, age) and information on the infant (e.g., birth date, plurality, sex, birth 
weight, congenital anomalies, complications of labor and delivery). Because the 2003 revision of the standard 
US birth certificate added information about the use of infertility treatment, birth certificates could become an 
important source of information on the association between these treatments and maternal and child health. 
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Pregnancy Risk Assessment Monitoring System 
www.cdc.gov/prams
The Pregnancy Risk Assessment Monitoring System (PRAMS) is a joint project of CDC and state health 
departments. It uses surveys to collect state-specific, population-based data on maternal attitudes and 
experiences before, during, and shortly after pregnancy. The goal of the system is to improve the health of 
mothers and infants by reducing adverse outcomes, such as low birth weight, infant death and disease, and 
maternal disease. Selected states collect data on the use of infertility treatment. These data may provide useful 
information on the association between infertility and infertility treatments and adverse health outcomes for 
mothers and infants. 
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